SLC5A2 and Hypoglycemia: The mechanism of action of SGLT2-Is in the pathogenesis of DKA can account for the results of the present study, which reflect an increase in risk for DKA and no difference in risk for hypoglycemia in SGLT2-Is as compared to placebo.